JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265911

Human SRGN (Serglycin) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

SRGN KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 5 bp deletion in exon 1. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Sanger Sequencing - Human SRGN (Serglycin) knockout HeLa cell line (AB265911)
  • Sanger seq

Unknown

Sanger Sequencing - Human SRGN (Serglycin) knockout HeLa cell line (AB265911)

Allele-2 : 1 bp deletion in exon 1.

Sanger Sequencing - Human SRGN (Serglycin) knockout HeLa cell line (AB265911)
  • Sanger seq

Unknown

Sanger Sequencing - Human SRGN (Serglycin) knockout HeLa cell line (AB265911)

Allele-1 : 5 bp deletion in exon 1.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 1 and 5 bp deletion in exon 1

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265911-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265911 Human SRGN (Serglycin) knockout HeLa cell line", "number":"AB265911-CMP01" }, { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265911-CMP02" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab265911-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255928 Human wild-type HeLa cell line", "number":"AB265911-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab265911 Human SRGN (Serglycin) knockout HeLa cell line", "number":"AB265911-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265911-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265911 Human SRGN (Serglycin) knockout HeLa cell line", "number":"AB265911-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265911-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265911 Human SRGN (Serglycin) knockout HeLa cell line", "number":"AB265911-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
SRGN
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Serglycin also known as hematopoietic proteoglycan core protein is a critical component of the extracellular matrix with a mass of approximately 17 kDa. It plays an important mechanical role by serving as a scaffold for the attachment of glycosaminoglycan (GAG) chains. These chains help serglycin mediate the storage and secretion of various bioactive molecules. It is expressed predominantly in hematopoietic cells including mast cells neutrophils and macrophages and also in endothelial cells serving diverse biological functions through its ability to interact with a wide variety of molecules.
Biological function summary

Serglycin acts as a mediator of cell granule storage and release processes. It is essential in the storage of secretory granules in mast cells and is involved in the process of degranulation where it participates in inflammation response and hemostasis. Serglycin associates with various proteins forming complexes with them to facilitate the storage of inflammatory mediators such as histamine and proteases. Its ability to bind to and sequester these bioactive molecules plays significant roles in the regulation of both innate and adaptive immune responses.

Pathways

Serglycin is an integral part of the inflammatory response pathway and the coagulation cascade. In the inflammatory pathway it modulates the release and activity of key cytokines and chemokines thereby participating in the regulation of immune cell recruitment and activation. In the coagulation cascade it interacts with protease inhibitors and various clotting factors to regulate coagulation processes. Serglycin's relationships with proteins like cathepsin G and elastase further illustrate its involvement in these pathways enhancing the modulation of inflammatory and hemostatic responses.

Aberrations in Serglycin function or expression have been linked to several conditions including asthma and certain types of leukemia. In asthma it may influence the severity of the disease through its role in the storage and release of inflammatory mediators in mast cells. In leukemia especially acute myeloid leukemia alterations in Serglycin expression can affect leukemic cell survival and proliferation. These links between Serglycin and disease states often involve interaction with other proteins like chymase and platelet factor 4 which contribute to disease processes.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com